FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority Review. Fedratinib…
Read More...
Read More...
